Risks of in utero exposure to valproate
- PMID: 23613078
- PMCID: PMC3685023
- DOI: 10.1001/jama.2013.4001
Risks of in utero exposure to valproate
Comment on
-
Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.JAMA. 2013 Apr 24;309(16):1696-703. doi: 10.1001/jama.2013.2270. JAMA. 2013. PMID: 23613074 Free PMC article.
References
-
- Adedinsewo DA. Trends in Valproate Prescriptions for Non-Epilepsy Indications among Women Aged 15-44 Years U.S. 1996-2007 [A Population-Based Study] [master's thesis] Emory University; Atlanta, GA: 2012. [March 15, 2013]. https://etd.library.emory.edu/view/record/pid/emory:bqmst.
-
- Harden CL, Meador KJ, Pennell PB, et al. American Academy of Neurology. American Epilepsy Society Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73(2):133–141. - PMC - PubMed
-
- US Food and Drug Administration (FDA) [March 15, 2013];FDA Drug Safety Communication: Children Born to Mothers Who Took Valproate Products While Pregnant May Have Impaired Cognitive Development. FDA website. http://www.fda.gov/Drugs/DrugSafety/ucm261543.htm. June 30, 2011.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
